FDA needs more on Somaxon's insomnia drug Silenor
This article was originally published in Scrip
Executive Summary
Somaxon is to conduct additional analysis of the clinical data of its troubled insomnia drug Silenor (doxepin), as requested by the US FDA's division of neurology products, which met the company to discuss February's complete response letter.